Statistical modeling using preoperative prognostic variables in predicting extracapsular extension and progression after radical prostatectomy for prostate cancer

Military Medicine

Volumn 163, Issue 9, 1998, Pages 615-619

  Bauer, John J ^a,b   Connelly, Roger R ^b   Seterhenn, Isabell A ^b,c   Srivastava, Shiv ^b   McLeod, Dauid G ^a,b   Moul, Judd W ^a,b  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^c ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; HUMAN; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE EVALUATION; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; RECURRENCE RISK; REGRESSION ANALYSIS; STATISTICAL MODEL;

EID: 3643061394     PISSN: 00264075     EISSN: None     Source Type: Journal    
DOI: 10.1093/milmed/163.9.615     Document Type: Article

References (24)

1. Wasson JH, Cushman CC, Bruskewitz RC, Littenberg B, Mulley AG, Wernberg JE: A structured literature review of treatment for localized prostate cancer. Arch Fam Med 1993; 2: 487-93.
2. Paulson DF, Moul JW, Robertson JE, Walther PJ: Postoperative radiotherapy of the prostate for patients undergoing radical prostatectomy with positive margins, seminal vesicle involvement and/or penetration through the capsule. J Urol 1990; 143: 1178-82.
3. Hanks GE, Dawson AK: The role of external beam radiation therapy after prostatectomy for prostate cancer. Cancer 1986; 58: 2406.
4. Gerber GS, Rukstalis DB, Chodak GW: Correlation of prostate specific antigen and tumor grade with nodal status in men with clinically localized prostate cancer. J Urol 1993; 149: 448A. Abstract 940.
5. Kleer E, Larson-Keller JJ, Zinke H, Oesterling JE: Ability of preoperative serum prostate-specific antigen value to predict pathological stage and DNA ploidy: influence of clinical stage and tumor grade. Urology 1993; 41: 207.
6. Partin AW, Yoo J, Carter HB, Pearson JD, Chan DW, Epstein JI, Walsh PC: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993; 150: 110.
7. Partin AW, Rattan MW, Subong EN, Walsch PC, Wojno KJ, Oesterling JE, Scardino PT, Pearson JD: Combination of prostate-specific antigen, clinical stage and Gleason score to predict pathological stage of localized prostate cancer. JAMA 1997; 277: 1445-51.
8. D'Amico AV, Whittington R, Malkowicz SB, Schnall M, Tomaszewski J, Schulte D, Kao G, VanArsdalen K, Wein AA: A multivariable analysis of clinical factors predicting for pathological features associated with local failure after radical prostatectomy for prostate cancer. Int J Radiat Oncol Biol Phys 1994; 30: 293.
9. Partin AW, Piantadosi S, Marshall FF, et al: Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. Urology 1995; 45: 831-7.
10. Bauer JJ, Conelly RA, Sesterhenn IA, Deausen J, McLeod DG, Srivastava S, Moul JW: Biostatistical modeling using traditional preoperative and pathological prognostic variables in the selection of men at high risk for prostate cancer recurrence after radical prostatectomy for prostate cancer. J Urol 1998; 159: 929-33.
11. Epstein JI, Pizov G, Walsh PC: Correlation of pathological findings with progression after radical retropubic prostatectomy. Cancer 1993; 71: 3582-93.
12. Norberg M, Holberg L, Wheeler T, Magnusson A: Five year follow-up after radical prostatectomy for localized prostate cancer: a study of the impact of different tumor variables on progression. Scand J Urol Nephrol 1994; 28: 391-9.
13. Ravery V, Boccon-Gibod LA, Meulemans A, Dauge-Geoffroy MC, Toublanc M, Boccon-Gibod L: Predictive value of pathological features for progression after radical prostatectomy. Eur Urol 1994; 26: 197-201.
14. Epstein JI, Carmichael MJ, Pizov G, Walsh PC: Influence of capsular penetration on progression following radical prostatectomy: a study of 196 cases with long-term followup. J Urol 1993; 150: 135.
15. Bauer JJ, Sesterhenn IA, Mostofl FK, McLeod DG, Srivastava S, Moul JW: p53 nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy. Clin Cancer Res 1995; 1: 1295-300.
16. Bauer JJ, Sesterhenn IA, Mostofl FK, McLeod DG, Srivastava S, Moul JW: Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer patients. J Urol 1996; 156: 1511-6.
17. Bettencourt MC, Bauer JJ, Sesterhenn IA, Mostofl FK, McLeod DG, Moul JW: Ki-67 expression is an independent prognostic marker of recurrence in patients with organ confined prostate cancer after radical prostatectomy. J Urol 1996; 156: 1064-8.
18. Moul JW, Douglas TH, McCarthy WF, McLeod DG: Black race is an adverse prognostic factor for prostate cancer recurrence following radical prostatectomy in an equal access health care setting. J Urol 1996; 155: 1667-73.
19. Partin AW, Oesterling JE: The clinical usefulness of prostatic-specific antigen: update. J Urol 1994; 152: 1358-68.
20. Gleason DF: Histological grading and clinical staging of prostate carcinoma. In Urologie Pathology: The Prostate, pp 171-97. Edited by Tannenbaum M. Philadelphia. PA, Lea & Febinger, 1977.
21. Mostofi FK, Sesterhenn IA, Sobin LH: Histological Typing of Prostate Tumors. Geneva, World Health Organization, 1980.
22. Obovi M, Wheeler TM, Scardino PT: The American Joint Committee on Cancer and International Union Against Cancer TNM classification of prostate cancer. Cancer 1994; 73: 104-14.
23. Cox DR: Regression models and life tables (with discussion). J R Stat Soc B 1972; 34: 187-220.
24. Breslow NE: Statistical methods for censored survival data. Environ Health Perspect 1979; 32: 181-92.